Top Stock Reports for Facebook, Adobe & Amgen

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Facebook (FB),&nbsp;Adobe Systems (ADBE) and Amgen (AMGN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.” data-reactid=”20″>The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe Systems (ADBE) and Amgen (AMGN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="You can see&nbsp;all of&nbsp;today’s&nbsp;research reports here &gt;&gt;&gt;” data-reactid=”21″>You can see all of today’s research reports here >>>

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Facebook’s shares have outperformed the S&amp;P 500 over the past year (+24% vs. +5.1%). The Zacks analyst believes that Facebook is benefiting from growth in Instagram Stories and Feed, and expanding user base in the Asia Pacific.” data-reactid=”22″>Facebook’s shares have outperformed the S&P 500 over the past year (+24% vs. +5.1%). The Zacks analyst believes that Facebook is benefiting from growth in Instagram Stories and Feed, and expanding user base in the Asia Pacific.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The company helped people connect during the coronavirus pandemic. Notably, voice and video calling more than doubled on Messenger and WhatsApp. The launch of Messenger Rooms for video call, which can accommodate 50 people, and WhatsApp video support for up to eight users are noteworthy in this regard. Further, the GIPHY buyout will boost user engagement.” data-reactid=”23″>The company helped people connect during the coronavirus pandemic. Notably, voice and video calling more than doubled on Messenger and WhatsApp. The launch of Messenger Rooms for video call, which can accommodate 50 people, and WhatsApp video support for up to eight users are noteworthy in this regard. Further, the GIPHY buyout will boost user engagement.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="However, Facebook expects ad-sales to be hurt by weakness in travel and automotive industry. The company didn’t provide any specific revenue guidance for the second quarter of 2020 as well as the full year. Moreover, higher operating expense is expected to dent the operating margin in 2020 due to sluggish revenue growth.” data-reactid=”24″>However, Facebook expects ad-sales to be hurt by weakness in travel and automotive industry. The company didn’t provide any specific revenue guidance for the second quarter of 2020 as well as the full year. Moreover, higher operating expense is expected to dent the operating margin in 2020 due to sluggish revenue growth.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="(You can&nbsp;read the full research report on Facebook here &gt;&gt;&gt;)” data-reactid=”25″>(You can read the full research report on Facebook here >>>)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shares of Adobe have gained +30.1% over the past six months against the Zacks Software industry’s rise of +17.2%. The Zacks analyst is optimistic about Adobe’s market position, compelling product lines, solid adoption of Creative Cloud and Adobe marketing cloud.” data-reactid=”26″>Shares of Adobe have gained +30.1% over the past six months against the Zacks Software industry’s rise of +17.2%. The Zacks analyst is optimistic about Adobe’s market position, compelling product lines, solid adoption of Creative Cloud and Adobe marketing cloud.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The company is benefiting from strong demand for its creative products. Its Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth. Further, rising subscription revenues and solid momentum across the mobile apps are major positives.” data-reactid=”27″>The company is benefiting from strong demand for its creative products. Its Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth. Further, rising subscription revenues and solid momentum across the mobile apps are major positives.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Additionally, growth in emerging markets, robust online video creation demand and improving average revenue per user are tailwinds. However, lower end-market demand and exposure to Europe remain overhangs. High acquisition expenses do not bode well for margin expansion.” data-reactid=”28″>Additionally, growth in emerging markets, robust online video creation demand and improving average revenue per user are tailwinds. However, lower end-market demand and exposure to Europe remain overhangs. High acquisition expenses do not bode well for margin expansion.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="(You can&nbsp;read the full research report on Adobe here &gt;&gt;&gt;)” data-reactid=”29″>(You can read the full research report on Adobe here >>>)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Amgen’s shares have gained +28.4% over the past three months against the Zacks Biomedical and Genetics industry’s rise of +35.3%. The Zacks analyst believes that growth products like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars will drive sales this year.” data-reactid=”30″>Amgen’s shares have gained +28.4% over the past three months against the Zacks Biomedical and Genetics industry’s rise of +35.3%. The Zacks analyst believes that growth products like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars will drive sales this year.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="However, increasing competition for its legacy products will continue to hurt sales. Amgen boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the stake in China’s BeiGene.” data-reactid=”31″>However, increasing competition for its legacy products will continue to hurt sales. Amgen boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the stake in China’s BeiGene.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen also expects a significant impact from coronavirus-related business disruption in Q2, which it expects to ease in the second half of 2020.&nbsp;&nbsp;” data-reactid=”32″>Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen also expects a significant impact from coronavirus-related business disruption in Q2, which it expects to ease in the second half of 2020.  

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="(You can&nbsp;read the full research report on Amgen here &gt;&gt;&gt;)” data-reactid=”33″>(You can read the full research report on Amgen here >>>)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Other noteworthy reports we are featuring today include Lowe’s (LOW), Regeneron Pharmaceuticals (REGN) and TJX Companies (TJX).” data-reactid=”34″>Other noteworthy reports we are featuring today include Lowe’s (LOW), Regeneron Pharmaceuticals (REGN) and TJX Companies (TJX).

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Zacks Top 10 Stocks for 2020” data-reactid=”35″>Zacks Top 10 Stocks for 2020

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?” data-reactid=”36″>In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Last year’s 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.” data-reactid=”37″>Last year’s 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Access Zacks Top 10 Stocks for 2020 today &gt;&gt;” data-reactid=”38″>Access Zacks Top 10 Stocks for 2020 today >>

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Sheraz Mian” data-reactid=”39″>Sheraz Mian

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Director of Research” data-reactid=”40″>Director of Research

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly&nbsp;Earnings Trends&nbsp;and&nbsp;Earnings Preview&nbsp;reports. If you want an email notification each time Sheraz publishes a new article, please&nbsp;click here&gt;&gt;&gt;” data-reactid=”41″>Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today’s Must Read